Anika Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY November 30, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY November 30, 2023 |
|---|---|---|---|---|---|
| Revenue | $112.8M | — | $119.9M | $120.8M | — |
| Gross profit | $63.8M | — | $76.0M | $82.5M | — |
| Operating income | -$11.1M | — | -$5.1M | $844,000 | — |
| Cost of revenue | $49.0M | — | $43.9M | $38.3M | — |
| Cash from operations | $11.2M | — | $5.4M | -$1.8M | — |
| Capital expenditure | $6.8M | — | $7.7M | $5.4M | — |
| Free cash flow | $4.4M | — | -$2.3M | -$7.2M | — |
| Share repurchases | $9.5M | — | $10.9M | $5.0M | — |
| Impairments | $0 | $0 | $2.5M | $62.2M | $0 |
| Total assets | $190.3M | — | $202.7M | $270.6M | — |
Shares outstanding 13.3M · Free float 76.0%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.